PROJECT 005-GASTROINTESTINAL CANCER RESEARCH PROGRAM PROJECT SUMMARY/ABSTRACT Cancers of the gastrointestinal tract represent some of the most common and most deadly malignancies in the United States and around the world. Within the catchment area of the Vanderbilt-Ingram Cancer Center (VICC) population of 3.6 million people, GI tract malignancies account for 14% of all new cancers and 16% of cancer deaths. The Gastrointestinal Cancer Research Program (GI), led by co-Leaders, Jordan Berlin, MD and Daniel Beauchamp, MD, has been a translational/clinical program within VICC since VICC?s inception. GI remains highly successful as measured by growth of extramural funding, recruitment of talented GI cancer-focused investigators, scientific training of young investigators, career development, high productivity of scientific research publications, competing for cancer-focused research grants, development of new technology such as non-invasive imaging methods, and expanding opportunities for patients with GI malignancies to benefit from translational science through participation in innovative clinical trials. Drs. Berlin and Beauchamp integrate the program members? efforts within GI and VICC, thereby empowering members and the larger VICC community to answer critical questions and generate high impact discoveries regarding mechanisms of GI tract carcinogenesis and cancer progression that will translate into effective preventive strategies, better treatments and outcomes for these malignancies. GI membership investigates the breadth of GI malignancies with special initiatives in colorectal (CRC), gastroesophageal (GE) and pancreatic cancers. GI is strengthened by close relationships with the Jim Ayers Institute for Precancer Detection and Diagnosis (Dan Liebler, MD, Director), the Epithelial Biology Center (Robert Coffey, MD, Director) and Phase I Research (Jordan Berlin, MD, Director). There are 37 program members from 9 departments and two schools. There is $11.7M in NCI funding and $4.9M in other peer reviewed cancer-related support for the last budget year. The program members have 538 publications; 29% that are intra-programmatic and 41% that inter-programmatic. The members also have 216 collaborative publications with investigators at other institutions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-22
Application #
9344318
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-09-01
Budget End
2018-08-31
Support Year
22
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
079917897
City
Nashville
State
TN
Country
United States
Zip Code
37232
Dahlman, Kimberly Brown; Weinger, Matthew B; Lomis, Kimberly D et al. (2018) Integrating Foundational Sciences in a Clinical Context in the Post-Clerkship Curriculum. Med Sci Educ 28:145-154
Covington, Brett C; Spraggins, Jeffrey M; Ynigez-Gutierrez, Audrey E et al. (2018) Response of Hypogean Actinobacterial Genera Secondary Metabolism to Chemical and Biological Stimuli. Appl Environ Microbiol :
Hong, Jun; Maacha, Selma; Belkhiri, Abbes (2018) Transcriptional upregulation of c-MYC by AXL confers epirubicin resistance in esophageal adenocarcinoma. Mol Oncol 12:2191-2208
Bolus, W Reid; Peterson, Kristin R; Hubler, Merla J et al. (2018) Elevating adipose eosinophils in obese mice to physiologically normal levels does not rescue metabolic impairments. Mol Metab 8:86-95
Ramsey, Haley E; Fischer, Melissa A; Lee, Taekyu et al. (2018) A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov 8:1566-1581
Wu, Jie; Cai, Hui; Xiang, Yong-Bing et al. (2018) Intra-individual variation of miRNA expression levels in human plasma samples. Biomarkers 23:339-346
Cardin, Dana B; Goff, Laura W; Chan, Emily et al. (2018) Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results : A phase I clinical trial. Invest New Drugs 36:442-450
Yang, Jinming; Kumar, Amrendra; Vilgelm, Anna E et al. (2018) Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms. Cancer Immunol Res 6:1186-1198
Alvarado, Gabriela; Ettayebi, Khalil; Atmar, Robert L et al. (2018) Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology 155:1898-1907
Sierra, Johanna C; Asim, Mohammad; Verriere, Thomas G et al. (2018) Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis. Gut 67:1247-1260

Showing the most recent 10 out of 2462 publications